IN BRIEF: RTW Biotech notes drug approval in China for investee Corxel

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in ...

Alliance News 15 November, 2024 | 10:02AM
Email Form Facebook Twitter LinkedIn RSS

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Notes Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd, formerly Ji Xing Pharmaceuticals Ltd, has had its new drug application for Aficamten accepted by China's National Medical Products Administration. Aficamten is a drug treatment for obstructive hypertrophic cardiomyopathy, a genetic heart condition diagnosed in around 130,000 to 330,000 patients in China, in which the heart muscle becomes abnormally thick and limits the heart's pumping function. The drug has also received breakthrough therapy designation from the US Food & Drug Administration. Corxel was founded and launched by RTW Investments in 2019.

Current stock price: USD1.55, up 0.5% in London on Friday morning

12-month change: up 37%

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
RTW Biotech Opportunities Ord 1.55 USD 0.45

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures